Evidence map›Paper›PMID 23428644›Full record

ReviewCardiology2013

High-density lipoprotein subfractions--what the clinicians need to know.

Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593487 (Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia), which is not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
36.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593487 phase4unknown statusstarted 2015, after this paper: background citation

Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia

Ran2015Enrolled300Registered outcomes1Posted comparisons0ConditionsCoronary Heart Disease, HyperlipemiaArmsRosuvastatin 10mg/d group, Rosuvastatin 20mg/d group
Open the trial in the graph
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 745 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Low HDL-The Challenge.Clinical medicine & research · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Angela PirilloCenter for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Milan, Italy.
Giuseppe Danilo Norata
Alberico Luigi Catapano
Istituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Bassini · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.

Indexed as

ApolipoproteinsCardiovascular DiseasesCholesterol Ester Transfer ProteinsEnzyme InhibitorsFatty Acids, Omega-3Fibric AcidsHumansHypolipidemic AgentsLipoproteins, HDLLiverMutationNiacinApolipoproteinsCholesterol Ester Transfer ProteinsEnzyme InhibitorsFatty Acids, Omega-3Fibric AcidsHypolipidemic AgentsLipoproteins, HDLNiacin

Identifiers

PMID23428644
OpenAlexW2048070048

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.